ProMetic Life Sciences Inc. (TSE:PLI)’s share price rose 0.6% during mid-day trading on Monday . The stock traded as high as C$1.56 and last traded at C$1.55. Approximately 257,534 shares changed hands during trading, a decline of 81% from the average daily volume of 1,374,512 shares. The stock had previously closed at C$1.56.
A number of equities research analysts have weighed in on PLI shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of ProMetic Life Sciences in a report on Monday, November 20th. National Bank Financial decreased their price objective on ProMetic Life Sciences from C$2.50 to C$2.00 and set a “sector perform” rating on the stock in a report on Wednesday, November 15th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. ProMetic Life Sciences has an average rating of “Buy” and a consensus price target of C$3.50.
The firm has a market capitalization of $1,140.00, a price-to-earnings ratio of -9.47 and a beta of 2.39.
In other news, Director Steven J. Burton sold 98,075 shares of the business’s stock in a transaction that occurred on Friday, January 19th. The stock was sold at an average price of C$1.54, for a total value of C$151,035.50.
TRADEMARK VIOLATION NOTICE: “ProMetic Life Sciences (PLI) Stock Price Up -0.6%” was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this article on another publication, it was illegally copied and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://sportsperspectives.com/2018/01/24/prometic-life-sciences-pli-stock-price-up-0-6.html.
About ProMetic Life Sciences
Prometic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.
Receive News & Ratings for ProMetic Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.